Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CERT
stocks logo

CERT

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
104.08M
+11.54%
0.100
+42.21%
104.42M
+10.12%
0.108
-17.02%
106.99M
+6.61%
0.120
-19.9%
Estimates Revision
The market is revising Upward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by -27.16%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.15%
In Past 3 Month
Stock Price
Go Down
down Image
-27.16%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 14.64 USD with a low forecast of 9.00 USD and a high forecast of 18.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
6 Hold
0 Sell
Moderate Buy
up Image0
Current: 10.540
sliders
Low
9.00
Averages
14.64
High
18.00
up Image0
Current: 10.540
sliders
Low
9.00
Averages
14.64
High
18.00
Morgan Stanley
Equal Weight
initiated
$16
2025-07-03
Reason
Morgan Stanley
Price Target
$16
2025-07-03
initiated
Equal Weight
Reason
Morgan Stanley assumed coverage of Certara with an Equal Weight rating and $16 price target. The firm says it awaits further potential updates on Certara's strategic review of the regulatory services business and management commentary regarding the near- or mid-term impact that may result from Certara's opportunity set coming from the FDA's previous announcement to gradually reduce animal testing in favor of new approach methodologies.
Barclays
Luke Sergott
Equal Weight -> Overweight
upgrade
$11 -> $14
2025-05-08
Reason
Barclays
Luke Sergott
Price Target
$11 -> $14
2025-05-08
upgrade
Equal Weight -> Overweight
Reason
Barclays analyst Luke Sergott upgraded Certara to Overweight from Equal Weight with a price target of $14, up from $11. The firm believes the company is more favorably positioned with potential macro and policy headwinds versus the majority of its peers sector. Shares at current levels offer an attractive entry point, the analyst tells investors in a research note. While it is still early days, Certara's simulation modeling functions more in the earlier stages of drug discovery, and the business is well positioned to capture Tailwinds from the transition away from animal models, contends Barclays.
Keybanc
Scott Schoenhaus
Buy
Maintains
$15 → $18
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$15 → $18
2025-04-16
Maintains
Buy
Reason
KeyBanc raised the firm's price target on Certara to $18 from $15 and keeps an Overweight rating on the shares. . Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Baird
Joe Vruwink
Hold
Maintains
$9 → $13
2025-04-11
Reason
Baird
Joe Vruwink
Price Target
$9 → $13
2025-04-11
Maintains
Hold
Reason
Baird analyst Joe Vruwink raised the firm's price target on Certara to $13 from $9 and keeps a Neutral rating on the shares. The firm updated its model after the FDA offered a strong endorsement for Biosimulation.
Barclays
Luke Sergott
Hold
Maintains
$13 → $11
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$13 → $11
2025-04-10
Maintains
Hold
Reason
Barclays lowered the firm's price target on Certara to $11 from $13 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Barclays
Luke Sergott
Hold
Maintains
$12 → $13
2025-02-28
Reason
Barclays
Luke Sergott
Price Target
$12 → $13
2025-02-28
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Certara Inc (CERT.O) is 22.75, compared to its 5-year average forward P/E of 52.07. For a more detailed relative valuation and DCF analysis to assess Certara Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
52.07
Current PE
22.75
Overvalued PE
88.26
Undervalued PE
15.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
26.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
38.31
Undervalued EV/EBITDA
14.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.07
Current PS
0.00
Overvalued PS
13.43
Undervalued PS
4.71

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

CERT News & Events

Events Timeline

(ET)
2025-07-08
08:10:56
Certara expands clinical technology collaboration with Merck
select
2025-05-29 (ET)
2025-05-29
08:04:18
Schrodinger appoints Mannix Aklian as chief commercial officer
select
2025-05-05 (ET)
2025-05-05
16:35:07
Certara affirms 2025 adjusted EPS outlook 42c-46c, consensus 45c
select
Sign Up For More Events
Sign Up For More Events

News

Preview
6.5
07-15NASDAQ.COM
Analysts Predict 15% Gains Ahead For The Holdings of USVM

  • ETF Analysis: The VictoryShares US Small Mid Cap Value Momentum ETF (USVM) has an implied analyst target price of $97.71 per unit, indicating a potential upside of 14.84% from its current trading price of $85.09.

  • Individual Holdings Performance: Notable underlying holdings like Certara Inc, BrightSpring Health Services Inc, and Two Harbors Investment Corp show significant upside potential based on analyst targets, with expected increases of 39.63%, 37.94%, and 27.84% respectively.

Preview
3.0
07-11NASDAQ.COM
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

  • Certara's Earnings Performance: Certara, Inc. has consistently surpassed earnings estimates in recent quarters, with an average surprise of 11.54%. The company is expected to report its next earnings on August 6, 2025, and currently holds a positive Earnings ESP of +2.44%, indicating potential for another earnings beat.

  • Market Trends and Investment Opportunities: The demand for data is driving growth in the semiconductor market, with new opportunities emerging for companies that provide hardware solutions. Investors are encouraged to utilize tools like the Earnings ESP Filter to identify promising stocks ahead of earnings releases.

Preview
7.5
07-08SeekingAlpha
Certara expands clinical technology partnership with Merck

  • Partnership Announcement: Certara has partnered with Merck to enhance the use of its Pinnacle 21 software platform, now including a metadata repository and improved data standards workflow management system.

  • Objective of Collaboration: This agreement aims to streamline regulatory submissions, continuing Merck's technological collaboration with Certara for greater efficiency.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Certara Inc (CERT) stock price today?

The current price of CERT is 10.54 USD — it has increased 1.25 % in the last trading day.

arrow icon

What is Certara Inc (CERT)'s business?

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

arrow icon

What is the price predicton of CERT Stock?

Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 14.64 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Certara Inc (CERT)'s revenue for the last quarter?

Certara Inc revenue for the last quarter amounts to 106.00M USD, increased 9.67 % YoY.

arrow icon

What is Certara Inc (CERT)'s earnings per share (EPS) for the last quarter?

Certara Inc. EPS for the last quarter amounts to 0.03 USD, decreased -200.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Certara Inc (CERT)'s fundamentals?

The market is revising Upward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by -27.16%.
arrow icon

How many employees does Certara Inc (CERT). have?

Certara Inc (CERT) has 1487 emplpoyees as of July 18 2025.

arrow icon

What is Certara Inc (CERT) market cap?

Today CERT has the market capitalization of 1.71B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free